Read Redeye's new equity report on Alzinova AB

.............................................................. 

GU Ventures share news and information about the business, its companies, and alumni companies.

..............................................................

Redeye AB has revisited the Alzinova equity story with the initiation of clinical trials with ALZ-101, our vaccine candidate in Alzheimer’s, an indication with a vast unmet medical need. "Now is the time when the case could start to heat up."

Click HERE to read the full updated equity report.